Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: Testosterone and ICI 182, 780 sensitive mechanism

BMC Neuroscience

Volumn 6, Issue , 2005, Pages

  Kendall, Sherie L ^a   Anderson, Caroline F ^b   Nath, Avindra ^b   Turchan Cholewo, Jadwiga ^a   Land, Cantey L ^c   Mactutus, Charles F ^c   Booze, Rosemarie M ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; ANDROSTANOLONE; CHOLESTEROL; COCAINE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GLYCOPROTEIN GP 120; HORMONE PRECURSOR; PROGESTERONE; SEX HORMONE; TESTOSTERONE; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT;

ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE CONTROL; DRUG MECHANISM; DRUG SENSITIVITY; FETUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN INTERACTION; TISSUE CULTURE; BRAIN; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; PATHOLOGY;

BRAIN; CELLS, CULTURED; COCAINE; ESTRADIOL; FETUS; GENE PRODUCTS, TAT; GONADAL STEROID HORMONES; HIV ENVELOPE PROTEIN GP120; HUMANS; NEUROPROTECTIVE AGENTS; TESTOSTERONE;

EID: 26444446596     PISSN: 14712202     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-6-40     Document Type: Article

References (81)

1. Buchanan R, Wang S, Huang C: Analyses of nursing home residents with HIV and dementia using the minimum data set. JAIDS 2001, 26: 246-255.
2. Dougherty RH, Skolasky RL, Jr., McArthur JC: Progression of HIV-associated dementia treated with HAART. AIDS Read 2002, 12: 69-74.
3. Chiesi A, Vella S, Dally L, Pedersen C, Danner S, Johnson A et al.: Epidemiology of AIDS dementia complex in Europe by the AIDS in Europe study group. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11: 39-44.
4. Davies J, Everall IP, Weich S, McLaughlin J, Scaravilli F, Lantos PL: HIV-associated brain pathology in the United Kingdom: an epidemiological study. AIDS 1997, 11: 1145-1150.
5. Bell JE, Brettle RP, Chiswick A, Simmonds P: HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 1998, 121: 2043-2052.
6. Berger JR, Nath A, Greenberg RN, Andersen AH, Greene RA, Bognar A et al.: Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 2000, 54: 921-926.
7. Holman B, Garada B, Johnson K, Mendleson J, Hallgring E, Teoh S et al.: A comparison of brain perfusion SPECT in cocaine abuse and AIDS dementia complex. J Nucl Med 1992, 33: 1312-1315.
8. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR: Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol 2001, 7: 66-71.
9. Mirsattari S, Power C, Nath A: Parkinsonism with HIV infection. Movement Disorders 1998, 13: 684-689.
10. Webber M, Shoenbaum E, Gourevitch M, Buono D, Klein R: A prospective study of HIV disease progression in female and male drug users. AIDS 1999, 13: 257-262.
11. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE et al.: Variable progression of HIV-associated dementia. Neurology 1998, 50: 1814-1820.
12. Margolin A, Avants S, Warburton L, Hawkins K: Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Patient Care and STDs 2002, 16: 255-267.
13. Holmberg SD: The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996, 86: 642-654.
14. Farzadegan JH, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB et al.: Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998, 352: 1510-1514.
15. Sterling T, Vlahov D, Astermborski J, Hoover D, Margolick J, Quinn T: Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001, 344: 720-725.
16. Squires KE: Treating HIV infection and AIDS in women. AIDS Read 2003, 13: 228-240.
17. Jover T, Tanaka H, Calderone A, Oguro K, Bennett M, Etgen A et al.: Estrogen protects against global ischemia-induced neuronal death and prevents activation of apoptotic signaling cascades in the hippocampal CA1. J Neurosci 2002, 22: 2115-2124.
18. Yang S-H, Liu R, Wu S, Simpkins J: The use of estrogens and related compounds in the treatment of damage from cerebral ischemia. Ann N Y Acad Sci 2003, 1007: 101-107.
19. Merchenthaler I, Dellovade T, Shugrue P: Neuroprotection by estrogen in animal models of global and focal ischemia. Ann N Y Acad Sci 2003, 1007: 89-100.
20. Rau S, Dubal D, Böttner M, Gerhold L, Wise P: Estradiol attenuates programmed cell death after stroke-like injury. J Neurosci 2003, 23: 11420-11426.
21. Sawada H, Ibi M, Kihara T, Urushitani M, Honda K, Nakanishi M et al.: Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J 2000, 14: 1202-1214.
22. Gajjar T, Anderson L, Dluzen D: Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003, 110: 1215-1224.
23. Tang M-T, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348: 429-432.
24. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A et al.: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997, 48: 1517-1521.
25. Manly J, Merchant C, Jacobs D, Small S, Bell K, Ferin M et al.: Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 2000, 54: 833-837.
26. Asthana S, Baker L, Craft S, Stanczyk F, Veith R, Raskind M et al.: High-dose estradiol improves cognition for women with AD. Neurology 2001, 57: 605-612.
27. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S: The effect of estrogen replacement on early Parkinson's disease. Neurology 1999, 52: 1417-1421.
28. Tsang K-L, Ho S-L, Lo S-K: Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000, 54: 2292-2298.
29. Wooten G, Curie L, Bovbjerg V, Lee J, Patrie J: Are men at greater risk for Parkinson's disease than women? J Neurosurg Psychiatry 2004, 75: 637-639.
30. Turchan J, Anderson C, Hauser KF, Sun Q, Zhang J, Liu Y et al.: Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2001, 2: 3.
31. Zemlyak I, Brooke SM, Sapolsky RM: Protection against gp120-induced neurotoxicity by an array of estrogenic steroids. Brain Res 2002, 958: 272-276.
32. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD: Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 2000, 47: 186-194.
33. Behl C, Skutella T, Lezoualc'h F, Post A, Widman M, Newton C et al.: Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997, 51: 535-541.
34. Culmsee C, Vedder H, Ravati A, Junker V, Otto D, Ahlemeyer B et al.: Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: Evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab 1999, 19: 1263-1269.
35. Moosmann B, Behl C: The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci U S A 1999, 96: 8867-8872.
36. Moss R, Gu J, Wong M: Estrogen: Nontranscriptional signaling pathway. In Recent Progress in Hormone Research. The Endocrine Society; 1997:33-69.
37. Woolley C: Effects of estrogen in the CNS. Curr Opin Neurbiol 1999, 9: 349-354.
38. Green P, Bishop J, Simpkins JW: 17α-Estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci 1997, 17: 511-515.
39. Hammond J, Quynh L, Goodyer C, Gelfand M, Trifiro M, LeBlanc A: Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem 2001, 77: 1319-1326.
40. Golden G, Mason P, Rubin R, Mason R: Biophysical membrane interactions of steroid hormones: A potential complementary mechanism of steroid action. Clinical Neuropharmacology 1998, 21: 181-189.
41. Jiang N, Chopp M, Stein D, Feit H: Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Res 1996, 735: 101-107.
42. Vongher J, Frye C: Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration. Pharmacol Biochem Behav 1999, 64: 777-785.
43. Ciriza I, Axcoitia I, Garcia-Segura LM: Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J Neuroendocrin 2004, 16: 58-63.
44. Chernecky CC, Berger BJe: Laboratory Tests and Diagnostic Procedures, 3 edn. Philadelphia: WB Saunders; 2001.
45. Rupprecht R, Friess E, Holsboer F: The Neuropsychopharmacological Potential of Neurosteroids. In Neurosteroids: A new regulatory function in the nervous system. Edited by Baulieu E-E, Robel P, Schumacher M. Totowa, NJ: Humana Press; 1999:349-364.
46. Zwain IH, Yen SSC, Cheng CY: Astrocytes cultured in vitro produce estradiol-17β and express aromatase cytochrome P-450 (P-450 AROM) mRNA. Biochim Biophys Acta 1997, 1334: 338-348.
47. Hojo Y, Hattori T, Enami T, Furukawa A, Suzuki K, Ishii H et al.: Adult male rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017α and P450 aromatase localized in neurons. Proc Natl Acad Sci U S A 2003, PNAS Early Edition: 1-6.
48. Daly R, Su T-P, Schmidt P, Pagliaro M, Pickar D, Ruiz-Lozano P: Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology 2003, 28: 317-331.
49. Labrie F, Bélanger A, Cusan L, Candas B: Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology. J Clin Endocrinol Metab 1997, 82: 2403-2409.
50. Papadopoulos V, Guarneri P, Krueger K, Guidotti A: Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: Regulation by a mitochondrial diazepam binding inhibitor receptor. Proc Natl Acad Sci U S A 1992, 89: 5113-5117.
51. Korneyev A, Pan B, Plol A, Romeo E, Guidotti A, Costa E: Stimulation of brain pregnenolone synthesis by mitochondrial diazepam binding inhibitor receptor ligands in vivo. J Neurochem 1993, 61: 1515-1524.
52. Stoffel-Wagner B: Neurosteroid metabolism in the human brain. Eur J Endocrinology 2001, 145: 669-679.
53. Weill-Engerer S, David J-P, Sazdovitch V, Liere P, Schumacher M, Delacourte A et al.: In vitro metabolism of dehydroepiandrosterone (DHEA) to 7α-hydroxy-DHEA and Δ5-androstene-3β,17β-diol in specific regions of the aging brain from Alzheimer's and non-demented patients. Brain Res 2003, 969: 117-125.
54. Zwain IH, Yen SSC: Dehydroepiandrosterone: Biosynthesis and metabolism in the brain. Endocrinology 1999, 140: 880-887.
55. McCullough L, Blizzard K, Simpson E, Ohran K, Hurn P: Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection. J Neurosci 2003, 23: 8701-8705.
56. Maccarrone M, Navarra M, Catani V, Corasaniti MT, Bagetta G, Finazazi-Agrò A: Cholesterol-dependent modulation of the toxicity of HIV-1 coat protein gp120 in human neuroblastoma cells. J Neurochem 2002, 82: 1444-1452.
57. Bonavia R, Bajetto A, Barbero S, Albini A, Noonan DM, Schettini G: HIV-1 Tat causes apoptotic death and calcium homeostasis alterations in rat neurons. Biochem Res Commun 2001, 288: 301-308.
58. Song L, Nath A, Geiger JD, Moore A, Hochman S: Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-D-aspartate receptors at an allosteric zinc-sensitive site. J Neurovirol 2003, 9: 399-403.
59. Bagetta G, Piccirilli S, Del Duca C, Morrone LA, Rombolà L, Nappi G et al.: Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. Neurosci Lett 2004, 356: 183-186.
60. Aksenova M, Aksenov MY, Nath A, Mactutus C, Booze R. Cocaine enhances oxidative stress-dependent toxicity of HIV-1 Tat in rat hippocampal cell cultures. Society for Neuroscience 573.8. 2004. Ref Type: Abstract
61. Nassogne M, Louahed J, Evrard P, Courtoy P: Cocaine induced apoptosis in cortical neurons in fetal mice. J Neurochem 1997, 68: 2442-2450.
62. Singer C, Rogers K, Dorsa D: Modulation of Bcl-2 expression: A potential component of estrogen protection in NT2 neurons. Neuroreport 1998, 9: 2565-2568.
63. Pike DJ: Estrogen modulates neuronal Bcl-xl expression and beta-amyloid induced apoptosis relevance to Alzheimer's disease. J Neurochem 1999, 72: 1552-1563.
64. Garnier M, DiLorenzo D, Albertini A, Maggi A: Identification of estrogen-responsive genes in neuroblastoma SK-ER3 cells. J Neurosci 1997, 17: 4591-4599.
65. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A: Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995, 37: 373-380.
66. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N et al.: Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 1996, 70: 1475-1480.
67. New D, Ma M, Epstein L, Nath A, Gelbard H: Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J Neurovirol 1997, 3: 168-173.
68. Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P et al.: Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 1994, 68: 4628-4635.
69. New DR, Maggirwar SB, Epstein LG, Dewhurst S, Gelbard HA: HIV-1 Tat induces neuronal death via tumor necrosis factor-α and activation of non-N-methyl-D-aspartate receptors by a NFκB-independent mechanism. The Journal of Biological Chemistry 1998, 273: 17852-17858.
70. Ma M, Nath A: Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 1997, 71: 2495-2499.
71. Gu J, Yassini P, Goldberg G, Shu W, Konat G, Wiggins R: Cocaine cytotoxicity in serum-free environment: C6 glioma cell culture. Neurotoxicology 1993, 14: 19-22.
72. Nassogne M, Evrard P, Courtoy P: Selective neuronal toxicity of cocaine in embryonic mouse brain cocultures. Proc Natl Acad Sci U S A 1995, 92: 11029-11033.
73. Bennet B, Hyde C, Pecora J, Clodfelter J: Long-term cocaine administration is not neurotoxic to cultured fetal mesencephalic dopamine neurons. Neurosci Lett 2003, 153: 210-214.
74. Robinson S, Enters E, Jackson G, Chinchilli V, Maher J, McDowell K et al.: Maternal and fetal brain and plasma levels of cocaine and benzoylecgonine after acute or chronic maternal intravenous administration of cocaine. J Pharmacol Exp Ther 1994, 271: 1234-1239.
75. Mactutus C, Herman A, Booze R: Chronic intravenous model for studies of drug (Ab)use in the pregnant and/or group-housed rat: an initial study with cocaine. Neurotoxicology and Teratology 1994, 16: 183-191.
76. Evans S, Cone E, Henningfield J: Arterial and venous cocaine plasma concentration in humans: Relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 1996, 279: 1345-1356.
77. Chiu F, Rozental R, Bassallo C, Lyman W, Spray D: Human fetal neurons in culture: intercellular communication and voltage- and ligand-gated responses. J Neurosci Res 1994, 38: 687-697.
78. Sanfeliu C, Sebastiá J, Kim SU: Methylmercury neurotoxicity in cultures of human neurons, astrocytes, neuroblastoma cells. Neurotoxicology 2001, 22: 317-327.
79. Messam CA, Hou J, Berman JW, Major EO: Analysis of the temporal expression of nestin in human fetal brain derived neuronal and glial progenitor cells. Developmental Brain Research 2002, 134: 87-92.
80. Fried G, Andersson E, Csöregh L, Enmark E, Gustafsson J-A, Aanesen A et al.: Estrogen receptor beta is expressed in human embryonic brain cells and is regulated by 17β-estradiol. Eur J Neurosci 2004, 20: 2345-2354.
81. Winter B: Statistical Principles in Experimental Design, 2 edn. New York: McGraw Hill; 1971.